ABSTRACT
OBJECTIVE To examine the associations of adolescent sugar-sweetened beverage (SSB) and sugar intake with risk of colorectal cancer (CRC) precursors.
DESIGN Prospective cohort study.
SETTING Nurses’ Health Study II (1998-2015), United States.
PARTICIPANTS 33106 women who completed a validated high school food frequency questionnaire about adolescent diet in 1998 and underwent lower gastrointestinal endoscopy between 1999 and 2015.
MAIN OUTCOME MEASURES Incident CRC precursors confirmed by medical record review.
RESULTS During follow-up, 2909 conventional adenoma, 1082 high-risk adenoma (≥1 cm in size, villous, high-grade dysplasia, or number ≥2), and 2355 serrated lesions were identified. Independent of adult intake, adolescent SSB and sugar intake was positively associated with risk of total and high-risk adenoma. Comparing ≥2 servings/day v <1 serving/week of SSB intake, multivariable odds ratios were 1.21 (95% confidence interval 1.00 to 1.47) for total and 1.21 (0.88 to 1.65) for high-risk adenoma. Per each 5% increment in calorie/day of total fructose intake, odds ratios were 1.17 (1.05 to 1.31) for total and 1.36 (1.14 to 1.62) for high-risk adenoma. By subsite, odds ratios were 1.25 (0.99 to 1.58) for proximal, 1.44 (1.12 to 1.84) for distal, and 1.74 (1.19 to 2.54) for rectal high-risk adenoma. Positive associations were stronger among women with low adolescent fruit, vegetable, or fiber intake. Among women with low fruit intake (<1.3 servings/day), odds ratios of total adenoma were 1.33 (1.11 to 1.59) for SSBs (≥1 serving/day v <1 serving/week) and 1.51 (1.26 to 1.82) for the highest quintile of total fructose (P≤0.024 for interaction). Neither SSB nor sugar intake during adolescence was associated with risk of serrated lesions.
CONCLUSIONS Independent of adult intake, adolescent SSB and sugar intake was positively associated with colorectal adenoma, especially high-risk rectal adenoma. Our findings suggest that adolescence may be a critical developmental period of enhanced susceptibility to high sugar intake, possibly promoting precancerous lesions of CRC arising through the adenoma-carcinoma sequence.
What is already known on this topic
- Relatively few studies have examined the association between sugar intake and colorectal neoplasia, and most prospective studies have reported null associations.
- Considering the long process of colorectal carcinogenesis and recent upward trends in early-onset colorectal cancer, early-life diet may be etiologically relevant.
- However, data on the relationship between high sugar intake during early-life and risk of colorectal neoplasia are lacking.
What this study adds
- Higher intake of sugar-sweetened beverages (SSBs) and sugars during adolescence was significantly associated with increased risk of total and high-risk adenoma, especially high-risk rectal adenoma, but not serrated lesions.
- Positive associations were stronger among women with low fruit, vegetable, or fiber intake during adolescence.
- Our results suggest that limiting sugar intake and replacing SSBs with healthy alternatives during early-life may help to reduce risk of colorectal cancer precursors.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form and declare: support from the National Institutes of Health for the submitted work. Dr. Ng has received institutional research funding from Pharmavite, Revolution Medicines, and Evergrande Group, has served on an advisory board for Seattle Genetics and Array Biopharma, and served as a consultant to X-Biotix Therapeutics. Dr. Meyerhardt has received institutional research funding from Boston Biomedical, has served as an advisor/consultant to Ignyta and COTA Healthcare, and served on a grant review panel for the National Comprehensive Cancer Network funded by Taiho Pharmaceutical. Dr. Chan has previously served as a consultant to Bayer Pharma AG, Pfizer Inc., and Boehringer Ingelheim for topics unrelated to this manuscript. Dr. Fuch reports consulting role for Agios, Amylin Pharmaceuticals, Bain Capital, CytomX Therapeutics, Daiichi-Sankyo, Eli Lilly, Entrinsic Health, Evolveimmune Therapeutics, Genentech, Merck, Taiho, and Unum Therapeutics. He also serves as a Director for CytomX Therapeutics and owns unexercised stock options for CytomX and Entrinsic Health. He is a co-Founder of Evolveimmune Therapeutics and has equity in this private company. He had provided expert testimony for Amylin Pharmaceuticals and Eli Lilly. The remaining authors report no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
The Nurses Health Study II was funded by the National Cancer Institute, National Institutes of Health (U01 CA176726, R01 CA67262, and U01 HL145386) and this project was funded by research grants R03 CA197879 (Wu), R21 CA222940 (Wu), R21 CA230873 (Wu, Ogino), R01 CA151993 (Ogino), R35 CA197735 (Ogino), R01 CA205406 (Ng), K24 DK098311 (Chan), R35 CA253185 (Chan), R37 CA246175 (Cao), K99 CA215314 (Song), R00 CA215314 (Song), and K07 CA188126 (Zhang). This work was also in part supported by an Investigator Initiated Grant from the American Institute for Cancer Research (AICR) to Dr. Wu. In addition, this work was supported by American Cancer Society Research Scholar Grant (RSG130476 to Zhang), the American Cancer Society Research Mentored Research Scholar Grant (MRSG-17-220-01 to Song), the Stuart and Suzanne Steele MGH Research Scholar Award (Chan), the Raymond P. Lavietes Foundation and the National Comprehensive Cancer Network Young Investigator Awards (Cao), the Bill and Melinda Gates Foundation (Willett), and the Breast Cancer Research Fund (Willett). Dr. Ng is supported in part by Department of Defense CA160344 and the Project P Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the institutional review boards of the Brigham and Women Hospital and Harvard T.H. Chan School of Public Health, and those of participating registries as required. Return of the mailed questionnaire was considered to imply informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email Addresses Hee-Kyung Joh: hkjoh{at}snu.ac.kr
Dong Hoon Lee: dhlee{at}mail.harvard.edu
Jinhee Hur: jhur{at}hsph.harvard.edu
Katharina Nimptsch: Katharina.Nimptsch{at}mdc-berlin.de
Yoosoo Chang: yoosoo{at}skku.edu
Hyojee Joung: hjjoung{at}snu.ac.kr
Xuehong Zhang : xuehong.zhang{at}channing.harvard.edu
Leandro F. M. Rezende: leandro.rezende{at}unifesp.br
Jung Eun Lee: jungelee{at}snu.ac.kr
Kimmie Ng : Kimmie_Ng{at}dfci.harvard.edu
Yuan Chen: Chen_Yuan{at}dfci.harvard.edu
Jeffrey A. Meyerhardt: Jeffrey_Meyerhardt{at}dfci.harvard.edu
Andrew T. Chan: ACHAN{at}mgh.harvard.edu
Tobias Pischon: tobias.pischon{at}mdc-berlin.de
Mingyang Song: msong{at}hsph.harvard.edu
Charles S. Fuchs: charles.fuchs{at}yale.edu
Walter C. Willett: wwillett{at}hsph.harvard.edu
Yin Cao: yin.cao{at}wustl.edu
Shuji Ogino: sogino{at}bwh.harvard.edu
Edward Giovannucci: egiovann{at}hsph.harvard.edu
Kana Wu: kwu{at}hsph.harvard.edu
Contributors H-KJ, EG, KW were involved in the study conception and design.
H-KJ, EG, and KW analyzed and interpreted the data.
H-KJ and DHL provided statistical expertise.
H-KJ and KW drafted the manuscript.
YC, SO, EG, and KW contributed equally to the manuscript.
H-KJ and KW are the guarantors.
All authors contributed to the interpretation of the results and critical revision of the manuscript for important intellectual content and approved the final version of the manuscript.
The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.
Data Availability
Data Sharing: No additional data available.
